Below is a comprehensive archive of press releases from MSF-USA. Use the options in the boxes below to filter results based on your preferences.

Country/Region

June 02, 2016

India must resist pressure from US lawmakers and pharmaceutical industry groups to block access to key medicines for millions of people worldwide

May 26, 2016

New York/Ise-Shima/Geneva—As the leaders of the G7 countries gather in Ise-Shima, Japan over the next two days, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is urging them to make a bold commitment to prioritize a better global response to public health emergencies and to take action to encourage the research and development (R&D) and affordable pricing of critical medicines.

May 16, 2016

US officials are expected to use this week’s APEC meeting to discuss extending the length of monopoly market protection for biologic medicines and vaccines.

May 11, 2016

Worst trade deal ever for access to medicines would restrict price-lowering generic competition and promote a broken innovation system

April 27, 2016

MSF hands over global petition as volunteers place 2,500 flowers in front of Pfizer’s headquarters in New York, representing the number of kids who die of pneumonia each day.

April 12, 2016

More than fifty groups have come together to demand that the US Congress reject the Trans-Pacific Partnership Trade Deal (TPP) due to provisions it contains that would undermine public health. In a letter sent to Congress today, the groups outlined the damaging effects the trade deal would have on public health, and said lawmakers should not vote for the TPP unless damaging provisions are removed.

March 18, 2016

Statement by Judit Rius Sanjuan, Doctors Without Borders/Médecins Sans Frontières’ (MSF) US Access Campaign Manager and Legal Policy Adviser 

March 10, 2016

Judit Rius Sanjuan, Access Campaign manager & legal policy advisor at Doctors Without Borders/Médecins Sans Frontières (MSF), made the following statement after KaloBios Pharmaceuticals obtained bankruptcy court permission to keep pursing a drug that could receive a US Federal Drug Administration Priority Review Voucher (PRV).

March 09, 2016

New York— A Senate committee voted today to add Zika to the list of diseases eligible for the US Federal Drug Administration (FDA) Priority Review Voucher (PRV) program for neglected diseases, but did not fix major loopholes that make the PRV program for neglected diseases ripe for abuse by pharmaceutical companies.

February 26, 2016

New York/New Delhi—In proceedings that could have major implications for millions of people waiting for affordable access to a lifesaving hepatitis C drug, the Indian Patent Office this week began hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges $1,000 per pill in the US.

Pages